Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
22 sept. 2021 09h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
22 sept. 2021 08h30 HE
|
Akari Therapeutics Plc
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic...
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium
10 sept. 2021 08h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2021 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces Private Placement
07 juil. 2021 09h15 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to...
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
29 juin 2021 16h01 HE
|
Akari Therapeutics Plc
Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe...
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
28 avr. 2021 08h00 HE
|
Akari Therapeutics Plc
A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiatedNomacopan has potential to replace long term steroid treatment (standard...
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
22 avr. 2021 07h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
20 avr. 2021 18h40 HE
|
Akari Therapeutics Plc
Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP), a severe dermatological disease with no...
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
12 avr. 2021 10h16 HE
|
Akari Therapeutics Plc
FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, April 12, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...